Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShares IssuedShort-Term Debt issuances
Growth Metrics
Income Statement
Others
Ratios

Regen BioPharma (RGBPP) Other Working Capital Changes (2016 - 2025)

Regen BioPharma (RGBPP) has disclosed Other Working Capital Changes for 11 consecutive years, with $28446.0 as the latest value for Q2 2025.

  • On a quarterly basis, Other Working Capital Changes rose 279.28% to $28446.0 in Q2 2025 year-over-year; TTM through Sep 2025 was -$47562.0, a 225.95% decrease, with the full-year FY2025 number at -$47562.0, down 225.95% from a year prior.
  • Other Working Capital Changes was $28446.0 for Q2 2025 at Regen BioPharma, up from -$50985.0 in the prior quarter.
  • In the past five years, Other Working Capital Changes ranged from a high of $48174.0 in Q3 2021 to a low of -$50985.0 in Q1 2025.
  • A 5-year average of $11.78 and a median of -$1029.0 in 2023 define the central range for Other Working Capital Changes.
  • Peak YoY movement for Other Working Capital Changes: soared 401550.0% in 2021, then crashed 167175.0% in 2022.
  • Regen BioPharma's Other Working Capital Changes stood at -$6856.0 in 2021, then crashed by 72.93% to -$11856.0 in 2022, then surged by 57.83% to -$5000.0 in 2023, then plummeted by 400.46% to -$25023.0 in 2024, then soared by 213.68% to $28446.0 in 2025.
  • Per Business Quant, the three most recent readings for RGBPP's Other Working Capital Changes are $28446.0 (Q2 2025), -$50985.0 (Q1 2025), and -$25023.0 (Q4 2024).